Clinical Trial

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-18
Trial Details
NCT Number NCT07513129
Lead Sponsor M.D. Anderson Cancer Center
Conditions T-cell Acute Lymphoblastic Leukemia, Lymphoma
Enrollment 18 participants
Start Date 2026-06-05
Primary Completion 2029-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12